Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Twist Bioscience Corp reported fiscal second quarter ended March 31, 2023 results: revenue Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of, net income Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, EPS $1.04 per share.
- Period
- fiscal second quarter ended March 31, 2023
- Revenue
- Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of
- Net income
- Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share
- EPS
- $1.04 per share
- Result
- reported results
Exact text from the filing
Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of fiscal 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Twist Bioscience Corp reported fiscal second quarter ended March 31, 2023 results: revenue Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of, net income Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, EPS $1.04 per share.
- Period
- fiscal second quarter ended March 31, 2023
- Revenue
- Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of
- Net income
- Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share
- EPS
- $1.04 per share
- Result
- reported results
Exact text from the filing
Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, compared to $60.7 million, or $1.13 per share, for the same period of fiscal 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
Twist Bioscience Corp reported fiscal 2023 results: revenue Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22.
- Period
- fiscal 2023
- Revenue
- Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22
- Result
- guidance update
Exact text from the filing
expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results – Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 – – Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 – -- Decisive Actions to Accelerate Path to Profitability -- SOUTH SAN
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Twist Bioscience Corp announced a restructuring with charges of between $9 and $11 million affecting worldwide (approximately 270 employees).
- Type
- restructuring
- Charge
- between $9 and $11 million
- Affected area
- worldwide
- Headcount
- approximately 270 employees
Exact text from the filing
On May 3, 2023, the Company’s board of directors approved a strategic restructuring plan, which includes a reduction in force affecting approximately 270 employees worldwide, representing approximately 25% of the Company’s total workforce. The Company expects the plan to be implemented beginning in the third quarter of fiscal year 2023 and substantially completed by the end of fiscal year 2023. The Company expects to incur pre-tax charges of between $9 and $11 million, consisting of cash expenditures for employee severance and related benefit costs.
View on SEC.gov